Novogen (KZIA) Stock Price, News & Analysis

Company Overview

Novogen Ltd is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer. Headquartered in Sydney, Australia, with research and development facilities in the United States and Europe, Novogen leverages a proprietary small‐molecule platform to identify compounds that modulate epigenetic regulators and immune checkpoints. The company’s pipeline includes both monotherapy candidates and combination regimens designed to address unmet medical needs in ovarian, breast and other solid tumors.

Since its inception in the early 2000s (following a corporate reorganization of an Australian pharmaceutical concern), Novogen has advanced multiple drug candidates through preclinical studies and into human trials. Its lead clinical asset is a highly selective epigenetic modulator currently in Phase 2 development for platinum‐resistant ovarian cancer, while follow‐on programs target additional histone demethylases and immune‐enhancing pathways. Novogen collaborates with academic institutions and contract research organizations across North America, Europe and Asia to accelerate IND‐enabling studies and optimize development timelines.

Historically listed on the Australian Securities Exchange before completing a secondary listing on NASDAQ, Novogen has built a global footprint that encompasses regulatory filings in key markets, manufacturing partnerships for GMP‐grade drug supply and licensing discussions aimed at regional commercialization. The company’s operations span early discovery through to late‐stage clinical development, supported by in-house pharmacology, toxicology and biomarker teams that help de-risk candidate selection and trial design.

Novogen’s leadership team brings together seasoned professionals from the pharmaceutical and biotech industries, including drug development veterans, regulatory specialists and commercial strategists. The executive roster is complemented by a scientific advisory board composed of oncology researchers and clinical investigators who provide guidance on translational studies and clinical protocol design. Together, this leadership cadre seeks to advance Novogen’s goal of delivering next-generation cancer therapies to patients around the world.

Key Stats

• Today's Range: $10.12 to $12.00
• 50-Day Range: $3.22 to $10.80
• 52-Week Range: $2.86 to $40.75
• Volume: 142,354 shs
• Average Volume: 378,809 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Strong Buy

Novogen Stock Analysis - MarketRank™

Novogen scored higher than 61% of companies evaluated by MarketBeat, and ranked 235th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Novogen has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Novogen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.81% of the float of Novogen has been sold short.

Short Interest Ratio / Days to Cover

Novogen has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novogen has recently decreased by 90.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novogen does not currently pay a dividend.

Dividend Growth

Novogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.81% of the float of Novogen has been sold short.

Short Interest Ratio / Days to Cover

Novogen has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novogen has recently decreased by 90.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

Novogen has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Novogen this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

1 people have added Novogen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Novogen is held by insiders.

Percentage Held by Institutions

Only 30.89% of the stock of Novogen is held by institutions.

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed this year?

Novogen's stock was trading at $8.85 at the beginning of the year. Since then, KZIA shares have increased by 31.6% and is now trading at $11.6450.

When did Novogen's stock split?

Novogen shares reverse split before market open on Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Novogen?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Today: 7/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• Previous Symbol: ASX:KZA
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Novogen: $14.00
• High Price Target: $15.00
• Low Price Target: $13.00
• Potential Upside/Downside: +29.6%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.51 million
• Price / Sales: 7.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.87) per share
• Price / Book: -1.09

Miscellaneous

• Outstanding Shares: 1,010,000
• Free Float: 997,000
• Market Cap: $10.91 million
• Optionable: Optionable
• Beta: 2.64